News Novartis edges ahead in CAR-T race Novartis has filed its CAR-T cell therapy with the FDA, giving it an edge over Kite Pharma and its rival treatment.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News Kite and Fosun appoint leader for CAR-T debut in China But rival Juno finally gives up on lead therapy.
Views & Analysis Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T... Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
News Kite’s CAR-T therapy most valuable pipeline orphan drug Drug tops list compiled by Evaluate Pharma
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
